HeraMED

Company Overview

Snapshot

Founded in October 2011 by Tal Slonim and David Groberman, HeraMED operates with 11–50 employees. The company has raised $23.76 million across 14 funding rounds from 4 investors. In December 2018, HeraMED completed its Initial Public Offering on the ASX.

Business overview

HeraMED is a Health Tech & Life Sciences company developing connected pregnancy monitoring solutions for home use. Its core products, HeraBEAT and HeraCARE, focus on fetal well-being and parental assurance. HeraBEAT is a medically accurate, smartphone-based fetal heartbeat monitor, while HeraCARE is a digital platform designed for comprehensive women's pregnancy care. The company is also developing future products like the EchoBEAT line of home-based monitoring devices and ORION, an AI-powered pregnancy monitoring system developed in cooperation with the Mayo Clinic. HeraMED serves the healthcare industry, targeting both providers and patients, including expectant mothers, across global markets.

Strategic signal

In March 2025, HeraMED reported a full-year 2024 earnings loss of AU$1.03 per share, a significant increase from the AU$0.025 loss in FY 2023. This financial update signals a period of increased operational costs or reduced revenue, which could impact investor sentiment and prompt a closer examination of the company's path to profitability and market strategy.

Company Intelligence Q&A

What was HeraMED's financial performance in the first half of 2025?

HeraMED reported a loss of AU$0.003 per share in the first half of 2025, an improvement compared to the AU$0.009 loss per share in the first half of 2024.

Did HeraMED collaborate with Mayo Clinic on any projects?

In July 2020, HeraMED announced a research collaboration with Mayo Clinic, which also participated as an investor in a funding round that month. This collaboration is focused on developing the ORION AI-powered pregnancy monitoring system.

Has HeraMED received FDA clearance for its products?

HeraMED received 510(k) clearance from the FDA for its HeraBEAT device in November 2019, enabling its use in the US market.

What was HeraMED's financial performance for the full year 2024?

HeraMED reported a full-year 2024 earnings loss of AU$1.03 per share, compared to an AU$0.025 loss in FY 2023.